Trioxsalen (trade names Oxsoralen, Oxsoralen-Ultra, Uvadex) is a drug used to treat psoriasis, eczema, and vitiligo. It is a member of the furanocoumarin family of drugs and is taken orally, with exposure to UVA light as part of a photochemotherapy regimen. It works by increasing skin sensitivity to UV light, which helps to repigment affected areas. Common side effects include nausea, itching, and skin irritation.
Trioxsalen, also known as trimethylpsoralen (TMP), trioxysalen (INN), or Trisoralen, is a medication that was used in conjunction with ultraviolet A (UVA) light therapy to treat certain skin conditions. However, it's important to note that trioxsalen has been discontinued by its manufacturer.
Here's a breakdown of what trioxsalen was used for:
- Vitiligo: This is a condition that causes a loss of skin color in patches. Trioxsalen, along with UVA light, aimed to activate skin cells (melanocytes) to repigment the discolored areas.
- Psoriasis (limited use): In some cases, trioxsalen with UVA light therapy might have been used to slow down the rapid growth of skin cells associated with psoriasis, reducing scaling and thickening.
How did it work?
Trioxsalen is classified as a photosensitizing agent. When taken by mouth and followed by UVA light exposure, it increased skin sensitivity to the light. This triggered a reaction in the targeted skin cells, affecting pigmentation (in vitiligo) or cell growth (in psoriasis).
Important points to consider:
- Due to discontinuation, trioxsalen is no longer a common treatment option. There are other therapies available for vitiligo and psoriasis.
- Even though discontinued, understanding trioxsalen can be relevant in some cases, such as coming across older medical records.
- Trioxsalen use came with potential side effects like skin redness, blistering, swelling, and itching.
- More importantly, it significantly increased sun sensitivity, raising the risk of sunburn, premature skin aging, and even skin cancer.